Dr. Becker has over 20 years of clinical experience and research applying functional principles in mental health treatment.
His early interest in the glutaminergic mechanisms of neurotransmission and NMDA receptor physiology has led to expertise in novel approaches to assessment and treatment of schizophrenia, alcohol-use disorder, and major depression. He was one of the first MDs in the U.S. administering ketamine for depression in the clinic, and is a world-recognized expert in translational science mapping the pharmacology of ketamine’s effect upon the GABAergic interneuron net to its healing transpersonal and symbolic psychedelic effects.
His expertise led to development of an effective nutraceutical product addressing NMDA-receptor abnormalities in cognitive dysfunction. He is currently co-founder and CSO at Bexson Biomedical, where they are developing novel subcutaneous formulations of ketamine and classical psychedelics for controlled delivery via a proprietary wearable patch pump delivery system for application in pain management and mental health disorders. He received his medical degree and psychiatric training at UCLA and maintains a clinical practice in Santa Barbara, CA focused in functional psychiatry and novel treatment approaches to mental health.